Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Commentary|Articles|January 15, 2026
Targeted Strategies, Systemic Therapies, and AI Advances Emerge as Central Themes From ASCO GI 2026
Author(s)Courtney Flaherty
Fact checked by: Chris Ryan
Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.
Advertisement
Advertisement
The
Related to this article
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Advertisement
Advertisement